Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension
Treprostinil Combined With Tadalafil for Pulmonary Hypertension
Objectives: To test whether the combined administration of the medications treprostinil(a prostacycline therapy), and tadalafil(a PDE-5 [ phosphodiesterase type 5]Inhibitor therapy) is better than the administration of…
- Trial name
- T2 (NCT01302444)
- Testing
- Tadalafil
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- Rhode Island Hospital
Pulmonary Artery Hypertension, Right Ventricular Dysfunction
Right Ventricular Pacing in Pulmonary Arterial Hypertension
In pulmonary arterial hypertension (PAH), progressive pulmonary vascular remodeling leads to supraphysiologic right ventricular (RV) afterload.
- Trial name
- NCT04194632
- Testing
- Temporary right ventricular pacing
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, San Francisco
Hypertension, Pulmonary
A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.
To provide riociguat therapy to eligible patients with PAH originating from Bayer-sponsored trials with BAY63-2521/ Riociguat / Adempas® who are currently or recently treated in these trials until lack of patient benefit as…
- Trial name
- RIALTO (NCT02759419)
- Testing
- Adempas (Riociguat, BAY63-2521)
- Where
- 9 sites in France, South Korea
- Volunteers
- 18 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity.
- Trial name
- NCT02253394
- Testing
- Ambrisentan plus Spironolactone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brigham and Women's Hospital
Pulmonary Arterial Hypertension (PAH)
Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare and serious condition that affects the blood vessels of the lungs and can significantly limit daily activities and quality of life.
- Trial name
- PROMISE (NCT07356375)
- Testing
- Selexipag
- Volunteers
- 32 people
- Sponsor
- University of Sao Paulo General Hospital
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH).
- Trial name
- NCT07600723
- Testing
- Sotatercept, Background PAH Therapy
- Where
- 3 sites in India
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Ventavis® Registry Protocol
The Ventavis® (iloprost) Registry is a multicenter, observational, U.S.-based study that longitudinally follows patients with pulmonary arterial hypertension (PAH) who have been receiving therapy with Ventavis® for at least 3…
- Trial name
- RESPIRE (NCT00902603)
- Testing
- Commercial Ventavis® (iloprost)
- Volunteers
- 148 people
- Sponsor
- Actelion
Pulmonary Hypertension
Evaluation of Feasibility of Ultrasonography Guided Pulmonary Artery Catheterization in Pulmonary Hypertension Diagnosis
Pulmonary artery catheters (PACs) that called Swan-Ganz catheters provide valuable information in select patient's especially pulmonary hypertension patiens.
- Trial name
- NCT07154927
- Where
- Egypt
- Volunteers
- 35 people
- Sponsor
- Mostafa K. Ahmed
Hypertension, Pulmonary
Effect of Exercise Training in Patients With Pulmonary Hypertension
Pulmonary Hypertension (PH) is a serious disease with a dismal prognosis when left untreated. Advances in medical therapy have improved survival according to recent registries and systematic reviews, but are associated with high…
- Trial name
- NCT02558582
- Testing
- respiratory and exercise therapy, respiratory and exercise therapy with supplemental oxygen
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I
Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by vascular remodelling resulting in elevated pressures in the pulmonary artery (PA).
- Conditions
- Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I, Pulmonary Arterial Hypertension
- Trial name
- RECOMPENSE (NCT06658522)
- Testing
- Sotatercept
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
Systemic Sclerosis, Pulmonary Hypertension
Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc)
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package- the Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa…
- Trial name
- NCT02278445
- Testing
- Doppler ultrasound, Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)
- Where
- Israel
- Sponsor
- Echosense Ltd.
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension
Sodium tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA isolated as the main pharmacologically active natural compound from a traditional Chinese herbal medicine,the dried root of Salvia miltiorrhiza…
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Cardiovascular Diseases, Lung Diseases
- Trial name
- STS (NCT01637675)
- Testing
- 20 mg sildenafil citrate by mouth, sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth
- Where
- China
- Volunteers
- 90 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan
the purpose of this study is: To assess the effect of BIA 5 1058 400 mg on the PK of bosentan. To assess the effect of bosentan on the PK of BIA 5 1058
- Trial name
- NCT04991207
- Testing
- BIA 5-1058, bosentan
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
The purpose of this multi-center, open-label, safety and tolerability study was to assess the addition of oral treprostinil (UT-15C sustained release [SR] tablets) to subjects currently receiving Tyvaso (treprostinil) inhalation…
- Trial name
- NCT01477333
- Testing
- UT-15C SR, Tyvaso Inhalation Solution
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- United Therapeutics
Thalassemia Major, Thalassemia Intermedia
Prevalence of Pulmonary Hypertension (PAH) in Patients With Thalassemia
This is a multicenter observational case-control analysis lasting 12 months aimed at determining the prevalence of pulmonary hypertension (PAH) in patients with Thalassemia Major and Intermedia.
- Conditions
- Thalassemia Major, Thalassemia Intermedia, Pulmonary Arterial Hypertension
- Trial name
- PAH2010 (NCT01496963)
- Testing
- Physician standard-of-care according to ESC/ERS Guidelines
- Where
- 8 sites in Italy
- Volunteers
- 1,500 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
Pulmonary Arterial Hypertension
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension.
- Trial name
- EPIMODE (NCT07761572)
- Testing
- CS1
- Volunteers
- 126 people
- Sponsor
- Cereno Scientific AB
Pulmonary Arterial Hypertension (PAH)
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
A Study of HS135 for the Treatment of Pulmonary Arterial Hypertension in Adults
- Trial name
- NCT06493461
- Testing
- HS135
- Where
- 2 sites in Canada, Germany
- Volunteers
- 5 people
- Sponsor
- 35Pharma Inc., a GSK company
Pulmonary Arterial Hypertension
Effects of Adding Yoga Respiratory Training to Osteopathic Manipulative Treatment in Pulmonary Arterial Hypertension
The investigators planned a randomized controlled study to investigate the effects of adding yoga respiratory training to osteopathic manipulative treatment (OMT), and OMT alone on exhaled nitric oxide level and cardiopulmonary…
- Trial name
- NCT04076241
- Testing
- Osteopathic manipulative treatment, Yoga respiratory training
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- Istanbul University - Cerrahpasa
Pulmonary Hypertension
Acute Exposure to High Altitude on Pulmonary Artery Pressure and Right Heart Function (Echo) Under Exercise
Randomized crossover Trial in patients with Pulmonary Hypertension (PAH, CTEPH) to assess the acute response to High Altitude (2500m above sea level) on pulmonary artery pressure and right heart function (Echo) under exercise.
- Trial name
- NCT03637179
- Testing
- Assessment at Low Altitude (470m above sea level), Exposure to High Altitude (2500m above sea level)
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension
Long-term Outcomes of Pregnant Women With PAH
The investigators intend to explore the characteristics and outcomes of pregnant women with PAH during different pregnancies and to provide applicable evidence for clinical practice.
- Trial name
- NCT04053296
- Testing
- Observational study
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital